{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:37:50Z","timestamp":1758281870463,"version":"3.44.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Drug-induced thrombotic microangiopathy (TMA) significantly impacts patient health and quality of life. This study aims to conduct an exploratory analysis of TMA reports and the most frequently associated drugs in the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed FAERS reports associated with TMA from the first quarter of 2004 to the fourth quarter of 2024. A disproportionality analysis was conducted to detect significant safety signals. Potential causative drugs were identified, and the top 30 medications with the highest number of TMA reports and strongest signal strengths were ranked accordingly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Analysis of 22,375,298 reports in the FAERS database identified 13,748 cases of thrombotic microangiopathy (TMA). Among the top 30 medications potentially associated with drug-induced TMA, antineoplastic and immunomodulatory agents predominated both in reporting frequency and signal strength metrics. Disproportionality analysis specifically revealed multiple drugs not currently labeled for TMA risk, with antineoplastic agents comprising the majority. Notably, several less frequently implicated agents - including micafungin, foscarnet, ketoprofen, and atovaquone - also demonstrated significant associations. These pharmacovigilance signals require cautious interpretation given the inherent limitations in establishing definitive causality through spontaneous reporting data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our comprehensive analysis of drug rankings and signal strengths associated with TMA in FAERS underscores the critical role of pharmacovigilance in identifying and understanding drug-induced TMA. These findings necessitate further research to validate the observed associations and to develop effective risk management strategies, ultimately improving patient outcomes. This study provides valuable evidence to support the accurate clinical identification of drug-related TMA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1658963","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T22:10:20Z","timestamp":1758233420000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the top 30 drugs associated with drug-induced thrombotic microangiopathy based on the FDA adverse event reporting system"],"prefix":"10.3389","volume":"16","author":[{"given":"Yi","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanmin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjiao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1038\/bcj.2016.62","article-title":"Thrombotic microangiopathy during carfilzomib use: case series in Singapore","volume":"6","author":"Chen","year":"2016","journal-title":"Blood Cancer J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1053\/j.ajkd.2004.02.010","article-title":"Non-enteropathic hemolytic uremic syndrome: causes and short-term course","volume":"43","author":"Constantinescu","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e071752","DOI":"10.1136\/bmj-2022-071752","article-title":"Characterization and corroboration of safety signals identified from the US food and drug administration adverse event reporting system, 2008-19: cross sectional study","volume":"379","author":"Dhodapkar","year":"2022","journal-title":"BMJ"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/ajh.26246","article-title":"Adverse events reported to the U.S. food and drug administration adverse event reporting system for tisagenlecleucel","volume":"96","author":"Dores","year":"2021","journal-title":"Am. J. Hematol."},{"key":"B7","unstructured":"Drugs@FDA: FDA-approved drugs\n          \n          \n          2025"},{"key":"B8","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1182\/blood-2002-10-3250","article-title":"166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1\/2 trials","volume":"102","author":"Giralt","year":"2003","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"E373","DOI":"10.1002\/ajh.27104","article-title":"Drug-induced thrombotic microangiopathy and thrombotic thrombocytopenic purpura: a systematic review, 2018-2023","volume":"98","author":"Khan","year":"2023","journal-title":"Am. J. Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/cpt.3139","article-title":"Drug-induced acute pancreatitis: a real-world pharmacovigilance study using the FDA adverse event reporting System database","volume":"115","author":"Li","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/1097-0142(1971)28:5<1314::aid-cncr2820280534>3.0.co;2-d","article-title":"Renal toxicity in man treated with mitomycin C","volume":"28","author":"Liu","year":"1971","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1088031","DOI":"10.3389\/fphar.2022.1088031","article-title":"Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/01.ede.0000113273.14807.53","article-title":"Incidence of thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome","volume":"15","author":"Miller","year":"2004","journal-title":"Epidemiology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.11406\/rinketsu.59.389","article-title":"Transplantation-associated thrombotic microangiopathy confirmed by renal biopsy","volume":"59","author":"Miyamoto","year":"2018","journal-title":"Rinsho Ketsueki"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e258","DOI":"10.1097\/MJT.0b013e3181d5e401","article-title":"Micafungin-induced thrombotic thrombocytopenic purpura: a case report and review of the literature","volume":"18","author":"Nazzal","year":"2011","journal-title":"Am. J. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.5414\/CP203724","article-title":"Drug-induced thrombotic microangiopathy using the Japanese pharmacovigilance database","volume":"58","author":"Niinomi","year":"2020","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1053\/j.ajkd.2017.05.023","article-title":"Quinine-Induced thrombotic microangiopathy: a report of 19 patients","volume":"70","author":"Page","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2165\/00002018-200124070-00002","article-title":"Drug-induced thrombotic microangiopathy: incidence, prevention and management","volume":"24","author":"Pisoni","year":"2001","journal-title":"Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13256-020-2349-4","article-title":"Thrombotic microangiopathy and liver toxicity due to a combination therapy of leflunomide and methotrexate: a case report","volume":"14","author":"Pliquett","year":"2020","journal-title":"J. Med. Case Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the Oklahoma registry and the BloodCenter of Wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"Am. J. Hematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pds.615","article-title":"The role of databases in drug postmarketing surveillance","volume":"10","author":"Rodriguez","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"105.e1","DOI":"10.1016\/j.jtct.2023.10.002","article-title":"Allogeneic hematopoietic cell transplantation for juvenile myelomonocytic leukemia with a busulfan, fludarabine, and melphalan regimen: JPLSG JMML-11","volume":"30","author":"Sakashita","year":"2024","journal-title":"Transpl. Cell Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2024.07.1456","article-title":"Evaluation of anticancer therapy-related dermatologic adverse events: insights from food and drug Administration\u2019s adverse event reporting system dataset","volume":"91","author":"Salah","year":"2024","journal-title":"J. Am. Acad. Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"E241","DOI":"10.1002\/ajh.25208","article-title":"Drug-induced thrombotic microangiopathy: an updated systematic review, 2014-2018","volume":"93","author":"Saleem","year":"2018","journal-title":"Am. J. Hematol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"15593258221093853","DOI":"10.1177\/15593258221093853","article-title":"Induction of erythrocyte membrane blebbing by methotrexate-induced oxidative stress","volume":"20","author":"Sattar","year":"2022","journal-title":"Dose Response"},{"key":"B29","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.bbmt.2004.03.002","article-title":"Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: the incidence is not reduced","volume":"10","author":"Shimoni","year":"2004","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B30","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2169\/internalmedicine.55.5703","article-title":"Clopidogrel-induced thrombotic microangiopathy in a patient with hypocomplementemia","volume":"55","author":"Tada","year":"2016","journal-title":"Intern. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/1078155215594417","article-title":"Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity","volume":"22","author":"Wiczer","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/cncr.20255","article-title":"High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma","volume":"100","author":"Widemann","year":"2004","journal-title":"Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1658963\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T22:10:21Z","timestamp":1758233421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1658963\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":32,"alternative-id":["10.3389\/fphar.2025.1658963"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1658963","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"article-number":"1658963"}}